Charles Hiram Randall - Oct 22, 2021 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Chief Strategy Officer
Signature
/s/ Charles Hiram Randall
Stock symbol
SABS
Transactions as of
Oct 22, 2021
Transactions value $
$0
Form type
4
Date filed
10/26/2021, 09:46 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Employee Stock Option (right to buy) Award +116K 116K Oct 22, 2021 Common Stock 116K $0.25 Direct F1, F2
transaction SABS Employee Stock Option (right to buy) Award +116K 116K Oct 22, 2021 Common Stock 116K $0.25 Direct F1, F2
transaction SABS Employee Stock Option (right to buy) Award +116K 116K Oct 22, 2021 Common Stock 116K $0.25 Direct F1, F2
transaction SABS Employee Stock Option (right to buy) Award +11.6K 11.6K Oct 22, 2021 Common Stock 11.6K $1.25 Direct F1, F2
transaction SABS Earnout Rights (Restricted Stock Units) Award +146K 146K Oct 22, 2021 Common Stock 146K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").
F2 The option is fully vested.
F3 Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]
F4 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.